REFERENCES
1. Conti F, Bionfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
2. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84.
3. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virüs infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
4. El-Seraq HB., Kanwal F., Richardson P., Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016;64:130-7.
5. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments:Controversy after the revolution. J Hepatol 2016;65:663-5.
6. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
7. Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumour recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
8. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma. Ann Intern Med 2013;158:329-37.
9. Ravi S, Axley P, Jones D, Kodali S, Simpson H, et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology 2017;152:911-3.
10. Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol 2016;65:1057-71.
11. Yang JD, Agel BA, Pungpapong S, Gores GJ, Roberts LR. Direct acting antiviral therapy and tumour recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol 2016;65:856-68.
12. Beste LA, Green PK, Berry K, Kogut MJ, Allison S, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 2017;67:32-9.
13. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174-81.
14. Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, et al. Lower incidence of hepatocelluler carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci 2015;60:573-81.
15. Innes H, Barclay ST, Hayes PC, Fraser A, Dillon JF, et al. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen. J Hepatol 2018;68:646-54.
16. Telep LE, Muramoto D, Osinusi A, Brainard DM, Reddy KR, et al. No ıncreased risk of hepatocellular carcinoma recurrence in patients following interferon-free, direct acting anti-viral treatment for hepatitis C virus: a cohort study using large-scale administrative medical claims data. J Hepatol 2017;66:S333-542.
17. Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with Direct-acting antivirals: an ERCHIVES study. Hepatology 2018;67:2244-53.
18. Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 2017;45:160-8.
19. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavo MR, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther 2017;46:688-95.
20. Virlogeux V, Pradat P, Hartig-Lavie K, Bailly F, Maynard M, et al. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. Liver International 2017;37:1122-7.
21. Mettke F, Schlevogt B, Deterding K, Wranke A, Smith A, et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol and Ther 2018;47:516-25.
22. Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 2018;155:411-21.
23. Marco VD, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, et al. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology 2016;151:130-9.
24. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153:996-1005.
25. Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol 2018;69:345-52.
26. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009;96:975-81.
27. Minami T, Tateishi R, Nakagomi R, Fujiwara N, Sato M, et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol 2016;65:1261-73.
